Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

22 Mar 2024

Abstract excerpt

In adult ALL, 5–10% of patients show KMT2A translocations ( KMT2A rearrangements) with only a few secondary alterations, implicating it as a leukemia-initiating factor [ 1 , 2 ]. Approximately 95% of all fusions in adult ALL are KMT2A :: AFF1 or KMT2A :: MLLT1 [ 3 ]. KMT2A -rearranged adult ALL patients are generally considered high-risk and are treated with intensified therapy, including allogeneic hematopoietic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38519799
DOI: 10.1038/s41375-024-02209-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemiaPMID 38519799Read ↗

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesSemantic proximity Read ↗

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read ↗

Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantationSemantic proximity Read ↗

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical AdvancesSemantic proximity Read ↗

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceSemantic proximity Read ↗

CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemiaSemantic proximity Read ↗

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study GroupSemantic proximity Read ↗

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemiaSemantic proximity Read ↗

Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?Semantic proximity Read ↗

<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based TherapiesSemantic proximity Read ↗

Measurable residual disease intervention in AML: a new therapeutic horizon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.